These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25978614)

  • 1. The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model.
    Ludidi S; Jonkers D; Elamin E; Pieters HJ; Schaepkens E; Bours P; Kruimel J; Conchillo J; Masclee A
    PLoS One; 2015; 10(5):e0123498. PubMed ID: 25978614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome.
    Wilcz-Villega EM; McClean S; O'Sullivan MA
    Am J Gastroenterol; 2013 Jul; 108(7):1140-51. PubMed ID: 23588236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase.
    Lee JW; Park JH; Park DI; Park JH; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
    Dig Dis Sci; 2010 Oct; 55(10):2922-8. PubMed ID: 20087660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study.
    Linsalata M; Riezzo G; D'Attoma B; Clemente C; Orlando A; Russo F
    BMC Gastroenterol; 2018 Nov; 18(1):167. PubMed ID: 30400824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome.
    Liang WJ; Zhang G; Luo HS; Liang LX; Huang D; Zhang FC
    Gut Liver; 2016 May; 10(3):382-90. PubMed ID: 26446924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multispecies probiotic protects gut barrier function in experimental models.
    Nébot-Vivinus M; Harkat C; Bzioueche H; Cartier C; Plichon-Dainese R; Moussa L; Eutamene H; Pishvaie D; Holowacz S; Seyrig C; Piche T; Theodorou V
    World J Gastroenterol; 2014 Jun; 20(22):6832-43. PubMed ID: 24944474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.
    Buhner S; Li Q; Vignali S; Barbara G; De Giorgio R; Stanghellini V; Cremon C; Zeller F; Langer R; Daniel H; Michel K; Schemann M
    Gastroenterology; 2009 Oct; 137(4):1425-34. PubMed ID: 19596012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders.
    Mujagic Z; Ludidi S; Keszthelyi D; Hesselink MA; Kruimel JW; Lenaerts K; Hanssen NM; Conchillo JM; Jonkers DM; Masclee AA
    Aliment Pharmacol Ther; 2014 Aug; 40(3):288-97. PubMed ID: 24943095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
    Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
    Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
    Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.
    Piche T; Barbara G; Aubert P; Bruley des Varannes S; Dainese R; Nano JL; Cremon C; Stanghellini V; De Giorgio R; Galmiche JP; Neunlist M
    Gut; 2009 Feb; 58(2):196-201. PubMed ID: 18824556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals.
    Russo F; Chimienti G; Linsalata M; Clemente C; Orlando A; Riezzo G
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):160-168. PubMed ID: 27750262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D.
    Singh P; Silvester J; Chen X; Xu H; Sawhney V; Rangan V; Iturrino J; Nee J; Duerksen DR; Lembo A
    United European Gastroenterol J; 2019 Jun; 7(5):709-715. PubMed ID: 31210949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Guilarte M; Vicario M; Martínez C; de Torres I; Lobo B; Pigrau M; González-Castro A; Rodiño-Janeiro BK; Salvo-Romero E; Fortea M; Pardo-Camacho C; Antolín M; Saperas E; Azpiroz F; Santos J; Alonso-Cotoner C
    Am J Gastroenterol; 2020 Dec; 115(12):2047-2059. PubMed ID: 32740086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling.
    Mahurkar-Joshi S; Rankin CR; Videlock EJ; Soroosh A; Verma A; Khandadash A; Iliopoulos D; Pothoulakis C; Mayer EA; Chang L
    Gastroenterology; 2021 Jun; 160(7):2409-2422.e19. PubMed ID: 33617890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M; Dainese R; Anty R; Saint-Paul MC; Nano JL; Gonthier N; Marjoux S; Frin-Mathy G; Bernard G; Hébuterne X; Tran A; Theodorou V; Piche T
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?
    Xu XJ; Liu L; Yao SK
    J Zhejiang Univ Sci B; 2016 Jan; 17(1):1-9. PubMed ID: 26739521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.
    Dunlop SP; Hebden J; Campbell E; Naesdal J; Olbe L; Perkins AC; Spiller RC
    Am J Gastroenterol; 2006 Jun; 101(6):1288-94. PubMed ID: 16771951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis.
    Gecse K; Róka R; Séra T; Rosztóczy A; Annaházi A; Izbéki F; Nagy F; Molnár T; Szepes Z; Pávics L; Bueno L; Wittmann T
    Digestion; 2012; 85(1):40-6. PubMed ID: 22179430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.